187 related articles for article (PubMed ID: 35739202)
1. Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy.
Flickinger JC; Staudt RE; Singh J; Carlson RD; Barton JR; Baybutt TR; Rappaport JA; Zalewski A; Pattison A; Waldman SA; Snook AE
NPJ Vaccines; 2022 Jun; 7(1):61. PubMed ID: 35739202
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
Flickinger JC; Singh J; Carlson R; Leong E; Baybutt TR; Barton J; Caparosa E; Pattison A; Rappaport JA; Roh J; Zhan T; Bashir B; Waldman SA; Snook AE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819976
[TBL] [Abstract][Full Text] [Related]
3. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
[TBL] [Abstract][Full Text] [Related]
4. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
[TBL] [Abstract][Full Text] [Related]
5. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.
Flickinger JC; Singh J; Yarman Y; Carlson RD; Barton JR; Waldman SA; Snook AE
Front Immunol; 2022; 13():855759. PubMed ID: 35355987
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
Snook AE; Baybutt TR; Hyslop T; Waldman SA
Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
[TBL] [Abstract][Full Text] [Related]
7. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
8. A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.
Cabrera-Mora M; Fonseca JA; Singh B; Zhao C; Makarova N; Dmitriev I; Curiel DT; Blackwell J; Moreno A
J Immunol; 2016 Oct; 197(7):2748-61. PubMed ID: 27574299
[TBL] [Abstract][Full Text] [Related]
9. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
[TBL] [Abstract][Full Text] [Related]
10. GUCY2C-targeted cancer immunotherapy: past, present and future.
Snook AE; Magee MS; Waldman SA
Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
[TBL] [Abstract][Full Text] [Related]
12. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
Xin KQ; Jounai N; Someya K; Honma K; Mizuguchi H; Naganawa S; Kitamura K; Hayakawa T; Saha S; Takeshita F; Okuda K; Honda M; Klinman DM; Okuda K
Gene Ther; 2005 Dec; 12(24):1769-77. PubMed ID: 16079886
[TBL] [Abstract][Full Text] [Related]
13. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
[TBL] [Abstract][Full Text] [Related]
14. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
15. [Preparation of recombinant adenovirus Ad5/F35 containing human WT1 and identification after recombinant adenovirus infected dendritic cells].
Zhang X; Jin Y; Zhang B; Chen H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Feb; 30(2):135-8. PubMed ID: 24491051
[TBL] [Abstract][Full Text] [Related]
16. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.
Wood LM; Paterson Y
Front Cell Infect Microbiol; 2014; 4():51. PubMed ID: 24860789
[TBL] [Abstract][Full Text] [Related]
17. [Immunogenicity of a chimeric adenovirus type 5 vector with type 35 fiber containing HIV-1 gag in mice].
Liu XL; Yu SQ; Feng X; Wang XL; Liu HM; Zhang XM; Li HX; Zhou L; Li ZL; Zheng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):5-7. PubMed ID: 17429520
[TBL] [Abstract][Full Text] [Related]
18. Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.
Fonseca JA; McCaffery JN; Caceres J; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
Vaccine; 2018 May; 36(20):2799-2808. PubMed ID: 29657070
[TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]